Univariate analysis | Multivariable analysis | |||||
---|---|---|---|---|---|---|
sdHR | 95% CI | p-value | sdHR | 95% CI | p-value | |
Age, per supplementary year | 0.99 | 0.99–1.00 | 0.16 | 0.99 | 0.98–1.00 | 0.084 |
SAPS II score, per one point increment | 1.01 | 1.01–1.01 | < 0.001 | 1.01 | 1.00–1.02 | 0.046 |
SOFA at admission, per supplementary point | 1.05 | 1.03–1.07 | < 0.001 | 0.01 | 0.98–1.05 | 0.48 |
Mild ARDS | 0.93 | 0.78–1.11 | 0.41 | |||
Moderate ARDS | 1.06 | 0.93–1.23 | 0.38 | |||
Severe ARDS | 1.21 | 1.02–1.42 | 0.025 | 1.00 | 0.77–1.30 | 0.99 |
Frailty scale, per supplementary point | 0.98 | 0.92–1.05 | 0.61 | |||
Male | 1.23 | 1.04–1.46 | 0.013 | 1.41 | 1.08–1.84 | 0.011 |
BMI, per supplementary point | 1.01 | 1.00–1.02 | 0.017 | 1.01 | 0.99–1.03 | 0.13 |
No comorbidities | 0.99 | 0.83–1.19 | 0.96 | |||
Tabaco consumption | 0.94 | 0.65–1.35 | 0.72 | |||
Chronic respiratory disease | 1.2 | 1.01–1.42 | 0.037 | 1.01 | 0.79–1.28 | 0.96 |
Chronic heart failure | 0.81 | 0.55–1.19 | 0.27 | |||
Hypertension | 1.02 | 0.88–1.17 | 0.83 | |||
Coronary artery disease | 1.04 | 0.83–1.29 | 0.76 | |||
Diabetes mellitus | 1.06 | 0.91–1.24 | 0.44 | |||
Hematological malignancy | 1.32 | 0.90–1.94 | 0.16 | 1.50 | 0.86–2.63 | 0.15 |
Immunodepression | 1.02 | 0.78–1.34 | 0.89 | |||
Solid malignancy | 0.67 | 0.34–1.33 | 0.25 | |||
Solid organ transplantation | 1.08 | 0.67–1.75 | 0.74 | |||
Chronic renal failure | 0.89 | 0.74–1.07 | 0.23 | |||
Cirrhosis | 0.87 | 0.37–2.06 | 0.75 | |||
Neuromuscular disease | 1.5 | 1.02–2.21 | 0.042 | 1.29 | 0.73–2.30 | 0.38 |
Long-term corticosteroids treatment | 1.07 | 0.76–1.5 | 0.69 | |||
Immunomodulatory drugs | 1.12 | 0.80–1.56 | 0.52 | |||
Treatment with NSAID | 1.18 | 0.88–1.58 | 0.27 | |||
Admission from a long-term care facility | 1.99 | 1.32–3.02 | 0.001 | 2.78 | 0.80–9.55 | 0.11 |
Admission from nursing home | 0.61 | 0.23–1.59 | 0.31 | |||
Admission from Home | 0.75 | 0.55–1.03 | 0.072 | 2.34 | 0.93–5.85 | 0.070 |
Time from hospital admission to ICU, per supplementary day | 1.01 | 0.99–1.03 | 0.2 | 1.03 | 1.02–1.05 | < 0.001 |
Period of admission | ||||||
Before 15th of March 2020 | 0.94 | 0.70–1.28 | 0.71 | |||
From 15th March to 31th of March 2020 | 1.07 | 0.93–1.23 | 0.34 | |||
From 1st April to 15 April 2020 | 0.9 | 0.76–1.06 | 0.21 | |||
After 15th of April 2020 | 1.01 | 0.74–1.39 | 0.93 | |||
Nurse/patient ratio | 0.93 | 0.84–1.04 | 0.20 | 0.91 | 0.78–1.06 | 0.23 |
Admission during night hours* | 1.01 | 0.88–1.16 | 0.86 | |||
Fever before admission | 1.17 | 0.96–1.43 | 0.12 | 0.95 | 0.71–1.27 | 0.72 |
Abdominal symptoms before admission | 0.90 | 0.77–1.06 | 0.20 | 1.19 | 0.93–1.51 | 0.17 |
Co-infection at admission | 1.28 | 1.02–1.61 | 0.032 | 1.47 | 1.07–2.02 | 0.17 |
Bacterial co-infection | 1.25 | 0.97–1.59 | 0.08 | |||
Viral co-infection | 0.14 | 0.03–0.78 | 0.025 | |||
ICU acquired pneumonia during period at risk for BSI | 0.84 | 0.73–0.98 | 0.025 | |||
Antiviral treatment before admission | 1.12 | 0.98–1.29 | 0.11 | 1.41 | 1.11–1.79 | 0.005 |
Immunomodulatory drugs during period at risk for BSI | 1.14 | 0.66–1.97 | 0.64 | |||
Tocilizumab during period at risk for BSI | 0.8 | 0.33–1.92 | 0.62 | |||
Intubation during period at risk for BSI | 2.28 | 1.89–2.74 | < 0.001 | 5.18 | 3.45–7.77 | < 0.001 |
ECMO during period at risk for BSI | 1.21 | 0.94–1.55 | 0.15 | 1.26 | 0.82–1.93 | 0.30 |
Thrombosis during period at risk for BSI | 0.76 | 0.59–0.98 | 0.037 | 0.85 | 0.58–1.26 | 0.42 |
Renal replacement therapy during period at risk for BSI | 0.29 | 0.22–0.40 | < 0.001 | 0.30 | 0.18–0.49 | < 0.001 |
Antibiotic during period at risk for BSI | 0.52 | 0.43–0.62 | < 0.001 | 0.45 | 0.33–0.61 | < 0.001 |
Corticosteroids during period at risk for BSI | 0.74 | 0.63–0.87 | < 0.001 | 0.79 | 0.62–1.01 | 0.063 |
Number of day at risk for BSI, per supplementary days | 0.97 | 0.96–0.98 | < 0.001 | 0.93 | 0.92–0.95 | < 0.001 |